[go: up one dir, main page]

MX2020012800A - Cannabinoides y usos de los mismos. - Google Patents

Cannabinoides y usos de los mismos.

Info

Publication number
MX2020012800A
MX2020012800A MX2020012800A MX2020012800A MX2020012800A MX 2020012800 A MX2020012800 A MX 2020012800A MX 2020012800 A MX2020012800 A MX 2020012800A MX 2020012800 A MX2020012800 A MX 2020012800A MX 2020012800 A MX2020012800 A MX 2020012800A
Authority
MX
Mexico
Prior art keywords
cannabinoid compounds
disease
pharmaceutical compositions
cannabinoids
compositions including
Prior art date
Application number
MX2020012800A
Other languages
English (en)
Inventor
Clifton D Leigh
Yuhua George Zhang
Kristos Adrian Moshos
Mark Tepper
Hongfeng Deng
Original Assignee
Corbus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corbus Pharmaceuticals Inc filed Critical Corbus Pharmaceuticals Inc
Publication of MX2020012800A publication Critical patent/MX2020012800A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención se refiere a compuestos cannabinoides, composiciones farmacéuticas que incluyen uno o más compuestos cannabinoides y al uso de las composiciones farmacéuticas que incluyen uno o más compuestos cannabinoides para el tratamiento de una enfermedad o condición (por ejemplo, una enfermedad fibrótica o una enfermedad inflamatoria) en un sujeto en necesidad de lo mismo.
MX2020012800A 2018-05-31 2019-05-31 Cannabinoides y usos de los mismos. MX2020012800A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862678689P 2018-05-31 2018-05-31
PCT/US2019/034965 WO2019232413A1 (en) 2018-05-31 2019-05-31 Cannabinoids and uses thereof

Publications (1)

Publication Number Publication Date
MX2020012800A true MX2020012800A (es) 2021-03-25

Family

ID=68697696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012800A MX2020012800A (es) 2018-05-31 2019-05-31 Cannabinoides y usos de los mismos.

Country Status (11)

Country Link
US (1) US20210284621A1 (es)
EP (1) EP3801505A4 (es)
JP (1) JP2021525803A (es)
KR (1) KR20210043494A (es)
CN (1) CN112739346A (es)
AU (1) AU2019278992A1 (es)
BR (1) BR112020024210A2 (es)
CA (1) CA3101626A1 (es)
IL (1) IL278881A (es)
MX (1) MX2020012800A (es)
WO (1) WO2019232413A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3145109A1 (en) * 2019-06-24 2020-12-30 Diverse Biotech, Inc. Cannabinoid conjugate molecules
WO2021067834A1 (en) * 2019-10-03 2021-04-08 Corbus Pharmaceuticals, Inc. Cannabinoids and uses thereof
WO2021113669A1 (en) * 2019-12-04 2021-06-10 Corbus Pharmaceuticals, Inc. Cannabinoids and uses thereof
WO2021113656A1 (en) * 2019-12-04 2021-06-10 Corbus Pharmaceuticals, Inc. Cannabinoids and uses thereof
EP4105204A1 (en) * 2021-06-14 2022-12-21 Swiss CannaPharmaceutical SA Conversion of thc, cbd and their derivatives to cannabinol
DK202330231A1 (en) * 2023-09-27 2025-04-10 Fertin Pharma As Cannabidiol for alleviating xerostomia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103410A1 (en) * 2002-06-06 2004-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
US20060128794A1 (en) * 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using (6aR,10aR)-delta8-tetrahydrocannabinol-11-OIC acids
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
KR20190139327A (ko) * 2013-02-12 2019-12-17 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
US9580400B2 (en) * 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
WO2019079677A1 (en) * 2017-10-20 2019-04-25 Corbus Pharmaceuticals, Inc. METHODS AND COMPOSITIONS RELATING TO 5- (1,1-DIMETHYLHEPTYL) -ORRESORCINOL ULTRAPUR

Also Published As

Publication number Publication date
KR20210043494A (ko) 2021-04-21
EP3801505A4 (en) 2022-07-20
WO2019232413A1 (en) 2019-12-05
US20210284621A1 (en) 2021-09-16
EP3801505A1 (en) 2021-04-14
IL278881A (en) 2021-01-31
JP2021525803A (ja) 2021-09-27
AU2019278992A1 (en) 2020-12-17
BR112020024210A2 (pt) 2021-02-17
CN112739346A (zh) 2021-04-30
CA3101626A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
MX2020012800A (es) Cannabinoides y usos de los mismos.
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
CY1122306T1 (el) Συνθεσεις που περιλαμβανουν bakthpiaka στελεχη
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1121938T1 (el) Αγωνιστες apj 4-υδροξυ-3-(ετερο¶ρυλ)πυριδινο-2-ονης για χρηση στη θεραπεια καρδιαγγειακων διαταραχων
MX386086B (es) Composicion de cannabis
EA201791299A1 (ru) Микроинкапсулированные композиции каннабиноидов
GEP20217316B (en) Aromatic sulfonamide derivatives
PE20180268A1 (es) Composiciones que comprenden cepas bacterianas
MA41013B1 (fr) Compositions comprenant des souches bactériennes
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
PH12020550051A1 (en) Glp-1 compositions and uses thereof
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
MA43335B1 (fr) Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
MX2024009894A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
PH12016501849A1 (en) 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
MX391963B (es) Beta-caseina a2 y prevencion de la inflamacion del intestino.
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
NZ798061A (en) Antimicrobial compounds, compositions, and uses thereof
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
DOP2017000085A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
PH12021550304A1 (en) Novel medicament for treating inflammatory bowel disease